Nanotechnology-based non-invasive strategies in ocular therapeutics: Approaches, limitations to clinical translation, and safety concerns

Contact Lens and Anterior Eye, Journal Year: 2025, Volume and Issue: unknown, P. 102367 - 102367

Published: Jan. 1, 2025

Language: Английский

---

Burst Release from In Situ Forming PLGA-Based Implants: 12 Effectors and Ways of Correction

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(1), P. 115 - 115

Published: Jan. 16, 2024

In modern pharmaceutical technology, modified-release dosage forms, such as in situ formed implants, are gaining rapidly popularity. These forms created based on a configurable matrix consisting of phase-sensitive polymers capable biodegradation, hydrophilic solvent, and the active substance suspended or dissolved it. The most used implants biocompatible biodegradable polymer, poly(DL-lactide-co-glycolide) (PLGA). Objective: This systematic review examines reasons for phenomenon ingredient “burst” release, which is major drawback PLGA-based likely ways to correct this improve quality with matrix. Data sources: Actual relevant publications PubMed Google Scholar databases were studied. Study selection: concept was theory developed during literature analysis 12 effectors burst release from forming PLGA. Only those studies that sufficiently fully disclosed one another component included. Results: resulted development approach called “12 Factor System”, considers various constant variable, endogenous exogenous factors can influence nature ‘burst release’ ingredients PLGA polymer-based implants. include porosity, polymer swelling, LA:GA ratio, end groups, molecular weight, structure, concentration, loading ingredients, combination, use co-solvents, addition excipients, change dissolution conditions. also considered different types kinetics possibility using “burst release” modify profile at site application form.

Language: Английский

---

Fostering the unleashing potential of nanocarriers-mediated delivery of ocular therapeutics

International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: 658, P. 124192 - 124192

Published: May 3, 2024

Ocular delivery is the most challenging aspect in field of pharmaceutical research. The major hurdle for controlled drugs to eye includes physiological static barriers such as complex layers cornea, sclera and retina which restrict drug from permeating into anterior posterior segments eye. Recent years have witnessed inventions conventional nanocarrier shown considerable enhancement delivering small large molecules across dynamic challenges associated with systems include limited contact time inadequate ocular bioavailability resulting solution drainage, tear turnover, dilution or lacrimation. To this end, various bioactive-based nanosized carriers including liposomes, ethosomes, niosomes, dendrimer, nanogel, nanofibers, lenses, nanoprobes, selenium nanobells, nanosponge, polymeric micelles, silver nanoparticles, gold nanoparticles among others been developed circumvent limitations dosage forms. These nanocarriers achieve enhanced permeation retention prolong release tissue due their better adherence. surface charge size (10–1000 nm) are important key factors overcome barriers. Various deliver active therapeutic timolol maleate, ampicillin, natamycin, voriconazole, cyclosporine A, dexamethasone, moxifloxacin, fluconazole treatment diseases. Taken together, a nutshell, book chapter provides comprehensive perspective on numerous facets special focus bioactive nanocarrier-based approaches, difficulties constraints involved fabrication nanocarriers. This also detailed invention applications ophthalmic therapeutics.

Language: Английский

---

Design, Synthesis, Formulation, and Bioevaluation of Trisubstituted Triazines as Highly Selective mTOR Inhibitors for the Treatment of Human Breast Cancer

Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 67(9), P. 7330 - 7358

Published: April 25, 2024

The aberrant activation of the PI3K/mTOR signaling pathway is implicated in various human cancers. Thus, development inhibitors targeting mTOR has attracted considerable attention. In this study, we used a structure-based drug design strategy to discover highly potent and kinase-selective inhibitor 24 (PT-88), which demonstrated an inhibitory IC50 value 1.2 nM without obvious inhibition against another 195 kinases from kinase profiling screening. PT-88 displayed selective MCF-7 cells (IC50: 0.74 μM) with high biosafety normal cells, autophagy induced by was implicated. After successful encapsulation lipodisc formulation, favorable pharmacokinetic profiles exerted large antitumor effect subcutaneous bearing nude mice model. Our study shows discovery using provides promising candidate for future development.

Language: Английский

---

Nanostructure-Mediated Transport of Therapeutics through Epithelial Barriers

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(13), P. 7098 - 7098

Published: June 28, 2024

The ability to precisely treat human disease is facilitated by the sophisticated design of pharmacologic agents. Nanotechnology has emerged as a valuable approach creating vehicles that can specifically target organ systems, effectively traverse epithelial barriers, and protect agents from premature degradation. In this review, we discuss molecular basis for barrier function, focusing on tight junctions, describe different pathways drugs use cross barrier-forming tissue, including paracellular route transcytosis. Unique features drug delivery applied systems are addressed: transdermal, ocular, pulmonary, oral delivery. We also how elements nanoscale such composition nanostructured architecture, be used enhance transepithelial tailor leverage biology an emerging theme in pursuit facilitating efficacious

Language: Английский

---

Active trans-corneal drug delivery with ocular adhesive micelles for efficient glaucoma therapy

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 377, P. 578 - 590

Published: Nov. 29, 2024

Language: Английский

---

Chitosan-Based Formulations for Enhanced Topical, Transdermal, and Ocular Drug Delivery

Advances in polymer science, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

An exploration of the ocular mysteries linking nanoparticles to the patho-therapeutic effects against keratitis

Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)

Published: March 6, 2025

Microbial keratitis, a sight-threatening corneal infection, remains significant global health concern. Conventional therapies using antimicrobial agents often suffers from limitations such as poor drug penetration, side effects, and occurrence of resistance, with prognosis. Novel treatment techniques, their unique properties targeted delivery capabilities, offers promising solution to overcome these challenges. This review delves into timely update the state-of-the-art advance therapeutics for keratitis treatment. The diverse microbial origins including viral, bacterial, fungal infections, exploring complex pathogenic mechanisms, followed by resistance mechanisms in pathogens are reviewed briefly. Importantly, emerging therapeutic techniques piezodynamic therapy, photothermal photodynamic nanoenzyme metal ion therapy summarized this showcasing potential traditional treatments. challenges future directions nanotechnology-based approaches discussed, focusing on safety, targeting strategies, combination therapies. aims inspire researchers revolutionize accelerate development functional materials different

Language: Английский

---

Ocular drug delivery systems based on nanotechnology: a comprehensive review for the treatment of eye diseases

Discover Nano, Journal Year: 2025, Volume and Issue: 20(1)

Published: May 3, 2025

Ocular drug delivery is a significant challenge due to the intricate anatomy of eye and various physiological barriers. Conventional therapeutic approaches, while effective some extent, often fall short in effectively targeting ocular diseases, resulting suboptimal outcomes factors such as poor bioavailability, frequent dosing requirements, systemic side effects, limited penetration through This review elucidates eye's physiology, prevalent traditional modalities, inherent pharmacokinetic pharmacodynamic limitations associated with these modalities. Subsequently, it delves into nanotechnology-based solutions, presenting breakthroughs nanoformulations nanocrystals, liposomes, dendrimers, nanoemulsions that have demonstrated enhanced stability, controlled release, deeper penetration. Additionally, explores range nanosized carriers, including nano-structured lipid hydrogels, nanogels, nanoenzymes, microparticles, conjugates, exosomes, nanosuspensions, viral vectors, polymeric nanoparticles, their applications. Unique insights include emerging innovations nanowafers transcorneal iontophoresis, which indicate paradigm shifts non-invasive delivery. Furthermore, sheds light on advantages platforms addressing challenges Though nano-based systems are drawing increasing attention potential enhance bioavailability efficacy, ends up emphasizing imperative need for further research drive innovation improve patient ophthalmology.

Language: Английский

---

Advancing fungal keratitis treatment: transitioning from conventional amphotericin B therapy to nanocarrier-based delivery systems

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: May 17, 2025

Language: Английский

---